Venturi Wealth Management LLC Invests $218,000 in Humana Inc. $HUM

Venturi Wealth Management LLC purchased a new stake in Humana Inc. (NYSE:HUM) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 892 shares of the insurance provider’s stock, valued at approximately $218,000.

Several other hedge funds have also recently bought and sold shares of HUM. Cary Street Partners Investment Advisory LLC increased its holdings in shares of Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after acquiring an additional 46 shares during the last quarter. Applied Finance Capital Management LLC raised its position in shares of Humana by 1.7% during the first quarter. Applied Finance Capital Management LLC now owns 2,943 shares of the insurance provider’s stock worth $779,000 after acquiring an additional 48 shares during the last quarter. Achmea Investment Management B.V. raised its position in shares of Humana by 0.5% during the first quarter. Achmea Investment Management B.V. now owns 10,379 shares of the insurance provider’s stock worth $2,746,000 after acquiring an additional 49 shares during the last quarter. Beech Hill Advisors Inc. boosted its position in shares of Humana by 6.1% during the first quarter. Beech Hill Advisors Inc. now owns 865 shares of the insurance provider’s stock worth $229,000 after purchasing an additional 50 shares in the last quarter. Finally, Atlas Brown Inc. boosted its position in shares of Humana by 0.9% during the second quarter. Atlas Brown Inc. now owns 6,369 shares of the insurance provider’s stock worth $1,557,000 after purchasing an additional 54 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Price Performance

Shares of NYSE HUM opened at $280.24 on Friday. The company has a market capitalization of $33.70 billion, a price-to-earnings ratio of 21.51, a P/E/G ratio of 1.65 and a beta of 0.42. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The company has a 50 day simple moving average of $279.45 and a two-hundred day simple moving average of $258.13. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $315.35.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a return on equity of 13.67% and a net margin of 1.28%.The company’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period last year, the firm posted $6.96 EPS. Humana has set its FY 2025 guidance at 17.000- EPS. Analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, September 26th. Humana’s dividend payout ratio (DPR) is 27.17%.

Analysts Set New Price Targets

Several research firms have recently weighed in on HUM. Sanford C. Bernstein upped their price objective on Humana from $269.00 to $341.00 and gave the stock an “outperform” rating in a research report on Friday, September 5th. Piper Sandler reduced their price target on Humana from $288.00 to $272.00 and set a “neutral” rating for the company in a research report on Thursday, July 31st. Bank of America increased their target price on Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a research note on Friday. Robert W. Baird lowered their price objective on Humana from $300.00 to $297.00 and set a “neutral” rating on the stock in a research note on Friday, July 25th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Humana in a report on Wednesday. Seven analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $298.00.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.